Calls to scrap the planned cap on self-education expenses
06 August, 2013AusBiotech has joined the growing chorus of Australian organisations and individuals who are opposed to the federal government’s plan to cap tax deductible self-education expenses at $2000 per Australian resident per annum.
ResMed FY13 profit grows 21%
05 August, 2013 by Dylan Bushell-EmblingResMed (ASX:RMD) has reported a 21% increase in FY13 net profit, but a decline in profit for the fourth quarter due to its $25m payout to the University of Sydney.
Avita enrols first patients for leg ulcer trial
02 August, 2013 by Dylan Bushell-EmblingAvita Medical (ASX:AVH) has signed up the first patients for a trial of its ReCell Spray on Skin product for the new application of treating venous leg ulcers.
Aussie biotechs must plan for weakened dollar
01 August, 2013 by Dylan Bushell-EmblingThe Australian Life Sciences Index outperformed the All Ordinaries in Q4, and the weaker dollar presents both challenges and opportunities for the sector, according to the latest PwC report.
Dr Greg Roger appointed as Medical and Scientific Technologies Supplier Advocate
01 August, 2013Medical technology industry expert Dr Greg Roger has been appointed by the federal government as the Supplier Advocate for the growing medical technologies market.
Bionomics signs up to US$172m deal with Merck
31 July, 2013 by Dylan Bushell-EmblingBionomics (ASX:BNO) has entered a small molecule pain drug research and option agreement with pharmaceutical giant Merck that could be worth up to US$172m.
Biotron completes recruitment for HIV/HCV trial
31 July, 2013 by Dylan Bushell-EmblingBiotron (ASX:BIT) has signed up the 12th and final subject for a phase II open-label trial of BIT225 in patients co-infected with - and receiving treatment for - HIV and HCV.
Student volunteer program for AusBiotech 2013 now open
30 July, 2013Applications are now open for the annual AusBiotech Student Volunteer Program at AusBiotech’s national conference, this year to be held in Brisbane (30 October-1 November).
Consegna picks manufacturer for nasal dilator
30 July, 2013 by Dylan Bushell-EmblingConsegna (ASX:CGP) has chosen ChinaMed as its global manufacturing partner for Turbine, a nasal dilator product bound for the Australian sporting goods market.
Final patient treated in PolyNovo BTM trial
30 July, 2013 by Dylan Bushell-EmblingPlastic surgeons have completed treatment for the last of 10 patients enrolled in a trial of PolyNovo’s NovoSorb BTM in free-flap donor site repair surgery.
Phosphagenics moving to phase II for TPM/oxycodone
29 July, 2013 by Dylan Bushell-EmblingPhosphagenics (ASX:POH) will move on to phase II trials of its oxycodone patch product, after demonstrating sustained delivery in phase I.
Opportunities for Australian biotechs in Switzerland
29 July, 2013 by Susan WilliamsonGeneva-based Campus Biotech is open to Australian biotech companies interested in establishing offices of R&D facilities in Europe.
Phylogica and Cubist team up to evaluate antimicrobial Phylomers
26 July, 2013Peptide drug discovery company Phylogica (ASX: PYC) is collaborating with US-based Cubist Pharmaceuticals (NASDAQ: CBST) to evaluate several of its antimicrobial Phylomers in models of multidrug-resistant bacterial infections.
Registrations open for Australia’s premier biotech investment and capital raising event
25 July, 2013AusBiotech and Beacon Events have joined forces to launch Australia’s premier event for biotech investment and capital raising - Australia Biotech Invest.
QRxPharma collaborates with Aesica
24 July, 2013Melbourne-based biopharmaceutical company QRxPharma (ASX: QRX) has announced a collaboration agreement with Aesica Pharmaceuticals subsidiary Aesica Formulation Development.
